Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
Agilent’s Net-Zero Emissions Targets Approved by the Science Based Targets InitiativePhoto, wide shot, wide-angle lens, soft focus,  Quarry, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-YQuR80w6IvxjemEoWYDXbEZo.png?st=2023-10-15T10%3A03%3A37Z&se=2023-10-15T12%3A03%3A37Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-10-14T14%3A03%3A01Z&ske=2023-10-15T14%3A03%3A01Z&sks=b&skv=2021-08-06&sig=/3q45HS%2B7KQiNIRh0W63diwmt7u%2BeQQMkMTkhvmYMtE%3D
Agilent’s Net-Zero Emissions Targets Approved by the Science Based Targets Initiative


Agilent Technologies Inc. (NYSE: A) today announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets

Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
STAAR Surgical to Report Third Quarter Results on November 1, 2023
STAAR Surgical to Report Third Quarter Results on November 1, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter

Humana’s Medicare Advantage Footprint in New Jersey Complete
Humana’s Medicare Advantage Footprint in New Jersey Complete


Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its health plans to Middlesex County, widening the company’s Medicare Advantage footprint to 100% of the state.



For the

EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer®

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25

Premier, Inc. to Report Fiscal 2024 First-Quarter Results and Host Conference Call on November 7, 2023
Premier, Inc. to Report Fiscal 2024 First-Quarter Results and Host Conference Call on November 7, 2023


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 first quarter on Tuesday, November 7, 2023, at approximately 6:30 a.m. ET. The company will

Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023
Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial

EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for

LivaNova Board Appoints J. Christopher Barry as New Director
LivaNova Board Appoints J. Christopher Barry as New Director


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the

Humana and Denver Health Sign Agreement to Expand Humana’s Medicare Advantage Provider Network in the Denver Area
Humana and Denver Health Sign Agreement to Expand Humana’s Medicare Advantage Provider Network in the Denver Area


Humana, a leading health and well-being company, and Denver Health, a comprehensive health and hospital system, have entered into an agreement that broadens access to care for Humana Medicare

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Humana #1 in Customer Satisfaction Among Medicare Advantage Plans in Florida
Humana #1 in Customer Satisfaction Among Medicare Advantage Plans in Florida


Leading health and well-being company Humana Inc. (NYSE: HUM) is ranked #1 in Florida in the J.D. Power ranking of Medicare Advantage Member Health Plans. Humana, the largest Medicare Advantage

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits